Vir Biotechnology has won FDA Fast Track designation for VIR-5500, a PSMA-targeted, dual-masked T-cell engager it is developing with Astellas Pharma for late-line metastatic castration-resistant prostate cancer (mCRPC). The San Francisco company announced the designation on 6 October 2026, alongside plans to start a pivotal Phase 3 program in 2027.
VIR-5500 in four figures
Figures from Vir Biotechnology's 6 October 2026 announcement and its February 2026 updated Phase 1 data (ASCO GU 2026).
A mask that only comes off inside the tumor
Vir Biotechnology built VIR-5500 around its PRO-XTEN masking technology: both binding arms of the bispecific antibody — the one that grabs prostate-specific membrane antigen (PSMA) on tumor cells and the one that engages a patient’s own CD3-bearing T cells — stay chemically masked in the bloodstream. Tumor-specific proteases in the tumor microenvironment cleave the masks, activating the molecule only where the cancer is. Vir says VIR-5500 is the only dual-masked PSMA-targeting T-cell engager currently in clinical trials, a field that also includes single-arm or unmasked PSMA x CD3 candidates from other sponsors.
The mechanism is a direct answer to a known problem with T-cell engagers: activating T cells throughout the body, not just at the tumor, drives the cytokine release syndrome (CRS) and neurotoxicity that have limited how these drugs are dosed and who can receive them. Updated Phase 1 data presented at ASCO GU 2026 showed CRS in roughly half of treated patients (29 of 58), but the company reported it was mostly low-grade fever that did not require prophylactic steroids — the kind of safety profile a masking strategy is meant to produce.
Three things the Phase 1 data show
A response in late-line disease
In RECIST-evaluable patients at the highest monotherapy dose tested, Vir reported a 45% objective response rate (5 of 11), in a population — late-line mCRPC after prior radioligand or chemotherapy — where new options are scarce.
CRS without routine steroids
Cytokine release syndrome occurred in about half of treated patients (29 of 58), predominantly low-grade fever, reported without prophylactic steroid use — a milder pattern than some unmasked T-cell engagers have shown in early trials.
A six-cohort expansion already running
Beyond late-line monotherapy, the Phase 1 trial includes cohorts combining VIR-5500 with androgen receptor pathway inhibitors in earlier, pre-taxane disease and with darolutamide in metastatic hormone-sensitive prostate cancer, broadening where the drug could eventually be used.
The crowded chase to mask a T-cell engager
VIR-5500 is not the only PSMA-targeted T-cell engager in development. Regeneron’s REGN4336 and Janux Therapeutics’ JANX007 are both PSMA x CD3 engagers in earlier-stage trials, and Janssen and Xencor have a PSMA x CD28 costimulatory candidate, JNJ-9401, in Phase 1. None of Vir’s publicly described rivals has disclosed a dual-masking approach covering both binding arms; most mask, if at all, only the T-cell-engaging side. Further upstream of all of them sits Novartis’ Pluvicto, a PSMA-targeted radioligand therapy already approved by FDA since 2022 and in routine use for later-line mCRPC — a different mechanism (a radioactive payload, not T-cell engagement) that VIR-5500 would likely be used after, not instead of, if it reaches approval.
A market built for a late-line arrival
$12.6B → $19.6B
Global castrate-resistant prostate cancer market, 2024 to 2030, as forecast by Global Industry Analysts.
Sources: Global Industry Analysts, Castrate-Resistant Prostate Cancer — Global Market Size report (via Research and Markets) · DelveInsight, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Insight (7MM, 2023 baseline)
Regulatory News outlook
We expect VIR-5500, if it clears Phase 3, to compete for a narrow late-line slice of this market rather than displace Pluvicto or chemotherapy outright, since Vir’s own trial design positions it after, not instead of, existing later-line standards.
How we got here: Global Industry Analysts’ published 7.7% compound annual growth rate on its $12.6 billion 2024 estimate reaches roughly $17.0 billion by 2028, the earliest plausible year for VIR-5500’s registrational data to read out; we treat that 2028 figure, not the full 2030 forecast, as the market VIR-5500’s first approval decision would actually land in.
VIR-5500 among prostate cancer's masked engagers
| Product | Mechanism | Masking | Stage | US status |
|---|---|---|---|---|
| VIR-5500 (Vir Biotechnology / Astellas) | PSMA x CD3 T-cell engager | PRO-XTEN dual-masked (both arms) | Phase 1, six expansion cohorts | FDA Fast Track, Oct 2026 |
| REGN4336 (Regeneron) | PSMA x CD3 T-cell engager | Not disclosed as dual-masked | Phase 1/2 | Investigational |
| JANX007 (Janux Therapeutics) | PSMA x CD3 T-cell engager | Company-described masking technology | Phase 1b | Investigational |
| Pluvicto (177Lu-PSMA-617, Novartis) | PSMA-targeted radioligand therapy | Not applicable — radioactive payload, not an engager | Marketed | FDA approved, 2022 |
From each company’s own announcements and public trial registrations; not a clinical comparison.
From a 2016 San Francisco bet to a Fast Track nod
VIR-5500's run to a designation
- April 2016
Vir Biotechnology founded
Incorporated in Delaware and based in San Francisco, built around antibody and immunology platforms for infectious disease and cancer.
- 2026
Astellas collaboration closes
Vir and Astellas Pharma close a global strategic collaboration to co-develop VIR-5500, under which Vir could earn up to roughly $1.7 billion in milestones plus royalties, with Astellas leading U.S. commercialization if the drug is approved.
- February 2026
Updated Phase 1 data at ASCO GU
Vir reports dose-dependent anti-tumor activity, including a 45% objective response rate at the highest monotherapy dose, with no new safety signals.
- October 2025
Combination cohort dosing begins
First patient dosed in Part 3 of the Phase 1 trial, testing VIR-5500 with androgen receptor pathway inhibitors in earlier-line disease.
- 6 October 2026
FDA Fast Track designation
FDA grants Fast Track status for VIR-5500 in late-line metastatic castration-resistant prostate cancer.
- 2027
Pivotal Phase 3 targeted
Vir and Astellas plan to begin registrational trials, subject to further Phase 1 data and FDA feedback.
What a late-line nod still has to prove
Fast Track designation speeds FDA’s review process and opens the door to rolling submission, but it is not a verdict on whether VIR-5500 works. The drug has not been studied in a randomized trial against an active comparator, and the 45% response rate the company highlights comes from a small, RECIST-evaluable subset of a dose-escalation study, not a registration-ready dataset.
“This Fast Track designation reflects the serious unmet need in late-line metastatic castration-resistant prostate cancer, and the momentum we are building with Astellas as we prepare to advance VIR-5500 toward pivotal Phase 3 development in 2027.” Marianne De Backer, President and Chief Executive Officer, Vir Biotechnology — 6 October 2026 announcement, as reported consistently across multiple outlets (Regulatory News could not open the primary release directly to confirm exact wording)
- Pivotal trial design: not yet disclosed; Vir and Astellas have said only that they plan to start a pivotal Phase 3 program in 2027.
- Combination data: cohorts testing VIR-5500 with androgen receptor pathway inhibitors and with darolutamide are still enrolling, with no efficacy readout yet reported.
- Competitive field: at least three other PSMA-targeted T-cell engagers (REGN4336, JANX007, JNJ-9401) are in earlier-stage development, and none has yet reported late-stage data either.
- Safety at scale: the CRS and response figures above come from 58 and 11 patients respectively — too few to know how the safety profile holds in a larger, more diverse population.
Sources & further reading
- Vir Biotechnology, “Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer,” press release, 6 October 2026. s203.q4cdn.com
- OncLive, “VIR-5500 Receives FDA Fast Track Designation in mCRPC,” reporting 8 October 2026 on the company's 6 October 2026 announcement. onclive.com
- ClinicalTrials.gov, “Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer,” NCT05997615. clinicaltrials.gov
- Vir Biotechnology investor relations — news releases. investors.vir.bio
- Vir Biotechnology, “Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA Targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer,” 9 October 2025. businesswire.com
- Global Industry Analysts, Castrate-Resistant Prostate Cancer — Global Market Size report, via Research and Markets. researchandmarkets.com
- DelveInsight, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Insight report. delveinsight.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did FDA grant Vir Biotechnology?
Fast Track designation for VIR-5500, a PSMA-targeted, PRO-XTEN dual-masked T-cell engager, for late-line metastatic castration-resistant prostate cancer (mCRPC), announced 6 October 2026. Fast Track speeds FDA's review process for drugs addressing a serious condition with unmet medical need; it is not an approval and does not establish that the drug works.
Is VIR-5500 approved to treat prostate cancer?
No. VIR-5500 remains investigational, in an open-label Phase 1 trial (NCT05997615) with six dose-expansion cohorts. Vir and Astellas plan to start a pivotal Phase 3 program in 2027, subject to further data and FDA feedback.
What does ‘dual-masked’ mean?
VIR-5500 uses Vir's PRO-XTEN technology to keep both binding arms of the bispecific antibody inactive until tumor-specific proteases cleave the masks inside the tumor microenvironment. Vir says it is the only dual-masked PSMA-targeting T-cell engager currently in clinical trials, among several PSMA x CD3 engagers in development.
What is Vir's partnership with Astellas?
Vir and Astellas Pharma closed a global strategic collaboration in 2026 to co-develop VIR-5500, under which Vir could earn more than a billion dollars in milestones plus royalties. Astellas leads U.S. commercialization if VIR-5500 is approved, with Vir retaining a co-promotion option.
